Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6%) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5%, 5-year DFS: 96.4 vs. 90.7%). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064–1073
Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203
Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO (2009) Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 11:R44
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. Engl J Med 353:1784–1792
Mook S, Van ‘t Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK (2011) Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585–597
Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs. symptomatic breast cancers and their impact on survival. Br J Cancer 101:1338–1344
Sihto H, Lundin J, Lehtimaki T, Sarlomo-Rikala M, Butzow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkila P, Joensuu H (2008) Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14:4103–4110
Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, Wallis M, Lawrence G (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117:1360–1368
Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R (2006) Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106:732–742
Ernst MF, Roukema JA, Coebergh JW, Repelaer van Driel OJ, van Beek MW, van der Sangen MJ, Voogd AC (2002) Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Res Treat 76:19–25
Allgood PC, Duffy SW, Kearins O, O’Sullivan E, Tappenden N, Wallis MG, Lawrence G (2011) Explaining the difference in prognosis between screen-detected and symptomatic breast cancers. Br J Cancer 104:1680–1685
Hutchison GB, Shapiro S (1968) Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 41:665–681
Shapiro S, Goldberg JD, Hutchison GB (1974) Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol 100:357–366
Zahl PH, Strand BH, Maehlen J (2004) Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 328:921–924
Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW (2008) Screen-detected vs. symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 98:1741–1744
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398
Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767–779
Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB (2004) Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10:6143–6151
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York
Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377
Colozza M, Sidoni A, Piccart-Gebhart M (2010) Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11:414–415
Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43:1–11
Korean Breast Cancer Society (2008) 2006–2008 Breast cancer facts & figures. Korean Breast Cancer Society, Seoul
Lim SM, Lee HY, Choi KS, Jun JK, Park EC, Kim Y, Han MA, Oh DK, Shim JI (2010) Trends of mammography use in a national breast cancer screening program, 2004–2008. Cancer Res Treat 42:199–202
Oh DK, Shim JI, Han M, Kim Y, Lee HY, Jun JK, Choi KS, Park EC (2010) Breast cancer screening in Korean women: report of the national cancer screening program in 2008. J Breast Cancer 13:299–304
Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N (2010) The state of the art of cancer control in 30 European countries in 2008. Int J Cancer 126:2700–2715
Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB, Kirkpatrick AE, Chetty U, Hepburn W, Smith A et al (1991) Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 64:108–113
Lindgren A, Holmberg L, Thurfjell E (1997) The influence of mammography screening on the pathological panorama of breast cancer. APMIS 105:62–70
de Roos MA, van der Vegt B, de Vries J, Wesseling J, de Bock GH (2007) Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast. Ann Surg Oncol 14:2097–2104
Cowan WK, Kelly P, Sawan A, Cunliffe WJ, Henry L, Higgs MJ, Lunt LG, Young JR, Horne CH, Angus B (1997) The pathological and biological nature of screen-detected breast carcinomas: a morphological and immunohistochemical study. J Pathol 182:29–35
Chu KC, Smart CR, Tarone RE (1988) Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 80:1125–1132
Cowan WK, Angus B, Henry J, Corbett IP, Reid WA, Horne CH (1991) Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 64:780–784
Paci E, Ponti A, Zappa M, Patriarca S, Falini P, Delmastro G, Bianchi S, Sapino A, Vezzosi V, Senore C, Crocetti E, Frigerio A, Zanetti R, Del Turco MR, Segnan N (2005) Early diagnosis, not differential treatment, explains better survival in service screening. Eur J Cancer 41:2728–2734
Biesheuvel C, Czene K, Orgeas CC, Hall P (2011) The role of mammography screening attendance and detection mode in predicting breast cancer survival-Is there added prognostic value? Cancer Epidemiol (in press). doi:10.1016/j.canep.2011.02.008
Gill PG (2004) Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 13:15–22
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489–492
Miles A, Cockburn J, Smith RA, Wardle J (2004) A perspective from countries using organized screening programs. Cancer 101:1201–1213
This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (A092255).
About this article
Cite this article
Kim, J., Lee, S., Bae, S. et al. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 131, 527–540 (2012). https://doi.org/10.1007/s10549-011-1836-0
- Breast cancer
- Molecular subtype